Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

16. maj 2014 opdateret af: Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise

The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control. For the open-label part of the study the objective is to estimate the efficacy and safety of BI 10773 when given for 24 weeks in patients with T2DM with very poor glycaemic control.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

986

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Belgien
      • Bruxelles, Belgien
        • 1245.20.32008 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgien
        • 1245.20.32011 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgien
        • 1245.20.32023 Boehringer Ingelheim Investigational Site
      • De Pinte, Belgien
        • 1245.20.32003 Boehringer Ingelheim Investigational Site
      • Deurne, Belgien
        • 1245.20.32015 Boehringer Ingelheim Investigational Site
      • Deurne, Belgien
        • 1245.20.32016 Boehringer Ingelheim Investigational Site
      • Gozée, Belgien
        • 1245.20.32025 Boehringer Ingelheim Investigational Site
      • Landen, Belgien
        • 1245.20.32022 Boehringer Ingelheim Investigational Site
      • Leopoldsburg, Belgien
        • 1245.20.32019 Boehringer Ingelheim Investigational Site
      • Linkebeek, Belgien
        • 1245.20.32024 Boehringer Ingelheim Investigational Site
      • Mouscron, Belgien
        • 1245.20.32021 Boehringer Ingelheim Investigational Site
      • Retie, Belgien
        • 1245.20.32027 Boehringer Ingelheim Investigational Site
      • Sint-Gillis-Waas, Belgien
        • 1245.20.32020 Boehringer Ingelheim Investigational Site
      • Tielt, Belgien
        • 1245.20.32018 Boehringer Ingelheim Investigational Site
      • Tremelo, Belgien
        • 1245.20.32026 Boehringer Ingelheim Investigational Site
  • Canada
    • British Columbia
      • Chilliwack, British Columbia, Canada
        • 1245.20.20011 Boehringer Ingelheim Investigational Site
      • Victoria, British Columbia, Canada
        • 1245.20.20018 Boehringer Ingelheim Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada
        • 1245.20.20015 Boehringer Ingelheim Investigational Site
    • New Brunswick
      • Moncton, New Brunswick, Canada
        • 1245.20.20012 Boehringer Ingelheim Investigational Site
    • Newfoundland and Labrador
      • Mount Pearl, Newfoundland and Labrador, Canada
        • 1245.20.20016 Boehringer Ingelheim Investigational Site
      • St. John's, Newfoundland and Labrador, Canada
        • 1245.20.20008 Boehringer Ingelheim Investigational Site
    • Ontario
      • Barrie, Ontario, Canada
        • 1245.20.20001 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1245.20.20019 Boehringer Ingelheim Investigational Site
      • London, Ontario, Canada
        • 1245.20.20010 Boehringer Ingelheim Investigational Site
      • London, Ontario, Canada
        • 1245.20.20017 Boehringer Ingelheim Investigational Site
      • Markham, Ontario, Canada
        • 1245.20.20003 Boehringer Ingelheim Investigational Site
      • Newmarket, Ontario, Canada
        • 1245.20.20009 Boehringer Ingelheim Investigational Site
      • Ottawa, Ontario, Canada
        • 1245.20.20013 Boehringer Ingelheim Investigational Site
      • Strathroy, Ontario, Canada
        • 1245.20.20005 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, Canada
        • 1245.20.20002 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, Canada
        • 1245.20.20006 Boehringer Ingelheim Investigational Site
    • Prince Edward Island
      • Charlottetown, Prince Edward Island, Canada
        • 1245.20.20014 Boehringer Ingelheim Investigational Site
      • Montague, Prince Edward Island, Canada
        • 1245.20.20007 Boehringer Ingelheim Investigational Site
    • Quebec
      • Trois Rivieres, Quebec, Canada
        • 1245.20.20021 Boehringer Ingelheim Investigational Site
  • Forenede Stater
    • Arizona
      • Mesa, Arizona, Forenede Stater
        • 1245.20.10124 Boehringer Ingelheim Investigational Site
      • Phoenix, Arizona, Forenede Stater
        • 1245.20.10108 Boehringer Ingelheim Investigational Site
    • Arkansas
      • Hot Springs, Arkansas, Forenede Stater
        • 1245.20.10150 Boehringer Ingelheim Investigational Site
    • California
      • Chino, California, Forenede Stater
        • 1245.20.10154 Boehringer Ingelheim Investigational Site
      • Santa Ana, California, Forenede Stater
        • 1245.20.10009 Boehringer Ingelheim Investigational Site
      • West Hills, California, Forenede Stater
        • 1245.20.10131 Boehringer Ingelheim Investigational Site
    • Colorado
      • Northglenn, Colorado, Forenede Stater
        • 1245.20.10038 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, Forenede Stater
        • 1245.20.10137 Boehringer Ingelheim Investigational Site
      • Miami, Florida, Forenede Stater
        • 1245.20.10006 Boehringer Ingelheim Investigational Site
      • Plantation, Florida, Forenede Stater
        • 1245.20.10085 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, Forenede Stater
        • 1245.20.10078 Boehringer Ingelheim Investigational Site
    • Georgia
      • Decatur, Georgia, Forenede Stater
        • 1245.20.10080 Boehringer Ingelheim Investigational Site
    • Indiana
      • Avon, Indiana, Forenede Stater
        • 1245.20.10128 Boehringer Ingelheim Investigational Site
      • Fishers, Indiana, Forenede Stater
        • 1245.20.10060 Boehringer Ingelheim Investigational Site
      • Indianapolis, Indiana, Forenede Stater
        • 1245.20.10065 Boehringer Ingelheim Investigational Site
    • Kansas
      • Arkansas City, Kansas, Forenede Stater
        • 1245.20.10117 Boehringer Ingelheim Investigational Site
      • Wichita, Kansas, Forenede Stater
        • 1245.20.10039 Boehringer Ingelheim Investigational Site
    • Kentucky
      • Louisville, Kentucky, Forenede Stater
        • 1245.20.10146 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Watertown, Massachusetts, Forenede Stater
        • 1245.20.10144 Boehringer Ingelheim Investigational Site
    • New Jersey
      • Brick, New Jersey, Forenede Stater
        • 1245.20.10115 Boehringer Ingelheim Investigational Site
    • Ohio
      • Carlisle, Ohio, Forenede Stater
        • 1245.20.10129 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, Forenede Stater
        • 1245.20.10045 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, Forenede Stater
        • 1245.20.10119 Boehringer Ingelheim Investigational Site
      • Gallipolis, Ohio, Forenede Stater
        • 1245.20.10130 Boehringer Ingelheim Investigational Site
    • Texas
      • Houston, Texas, Forenede Stater
        • 1245.20.10089 Boehringer Ingelheim Investigational Site
      • Hurst, Texas, Forenede Stater
        • 1245.20.10151 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, Forenede Stater
        • 1245.20.10155 Boehringer Ingelheim Investigational Site
  • Indien
      • Bangalore, Indien
        • 1245.20.91005 Boehringer Ingelheim Investigational Site
      • Bangalore, Indien
        • 1245.20.91006 Boehringer Ingelheim Investigational Site
      • Bangalore, Indien
        • 1245.20.91008 Boehringer Ingelheim Investigational Site
      • Belgaum, Indien
        • 1245.20.91003 Boehringer Ingelheim Investigational Site
      • Chennai, Indien
        • 1245.20.91004 Boehringer Ingelheim Investigational Site
      • Chennai, Indien
        • 1245.20.91009 Boehringer Ingelheim Investigational Site
      • Mumbai, Indien
        • 1245.20.91002 Boehringer Ingelheim Investigational Site
      • Mumbai, Maharastra, Indien
        • 1245.20.91007 Boehringer Ingelheim Investigational Site
      • Nagpur, Indien
        • 1245.20.91010 Boehringer Ingelheim Investigational Site
      • Tamil Nadu, Indien
        • 1245.20.91001 Boehringer Ingelheim Investigational Site
  • Irland
      • Co. Cork, Irland
        • 1245.20.35302 Boehringer Ingelheim Investigational Site
      • Co. Galway, Irland
        • 1245.20.35305 Boehringer Ingelheim Investigational Site
      • Co. Wexford, Irland
        • 1245.20.35303 Boehringer Ingelheim Investigational Site
      • Offaly, Irland
        • 1245.20.35304 Boehringer Ingelheim Investigational Site
      • Wexford, Irland
        • 1245.20.35306 Boehringer Ingelheim Investigational Site
  • Japan
      • Chiyoda-ku, Tokyo, Japan
        • 1245.20.81007 Boehringer Ingelheim Investigational Site
      • Chuo-ku, Tokyo, Japan
        • 1245.20.81001 Boehringer Ingelheim Investigational Site
      • Chuo-ku, Tokyo, Japan
        • 1245.20.81002 Boehringer Ingelheim Investigational Site
      • Ebetsu, Hokkaido, Japan
        • 1245.20.81005 Boehringer Ingelheim Investigational Site
      • Kamakura, Kanagawa, Japan
        • 1245.20.81004 Boehringer Ingelheim Investigational Site
      • Minato-ku, Tokyo, Japan
        • 1245.20.81003 Boehringer Ingelheim Investigational Site
      • Shinjuku-ku, Tokyo, Japan
        • 1245.20.81006 Boehringer Ingelheim Investigational Site
      • Shinjuku-ku, Tokyo, Japan
        • 1245.20.81008 Boehringer Ingelheim Investigational Site
      • Suita, Osaka, Japan
        • 1245.20.81009 Boehringer Ingelheim Investigational Site
      • Ube, Yamaguchi, Japan
        • 1245.20.81010 Boehringer Ingelheim Investigational Site
      • Urasoe, Okinawa, Japan
        • 1245.20.81012 Boehringer Ingelheim Investigational Site
      • Urasoe, Okinawa, Japan
        • 1245.20.81013 Boehringer Ingelheim Investigational Site
  • Kina
      • Beijing, Kina
        • 1245.20.86007 Boehringer Ingelheim Investigational Site
      • Beijing, Kina
        • 1245.20.86008 Boehringer Ingelheim Investigational Site
      • Guangzhou, Kina
        • 1245.20.86001 Boehringer Ingelheim Investigational Site
      • Guangzhou, Kina
        • 1245.20.86002 Boehringer Ingelheim Investigational Site
      • Guangzhou, Kina
        • 1245.20.86003 Boehringer Ingelheim Investigational Site
      • Guiyang, Kina
        • 1245.20.86012 Boehringer Ingelheim Investigational Site
      • Hangzhou, Kina
        • 1245.20.86020 Boehringer Ingelheim Investigational Site
      • Jinan, Kina
        • 1245.20.86049 Boehringer Ingelheim Investigational Site
      • Jingzhou, Kina
        • 1245.20.86018 Boehringer Ingelheim Investigational Site
      • Nanchang, Kina
        • 1245.20.86019 Boehringer Ingelheim Investigational Site
      • Nanjing, Kina
        • 1245.20.86010 Boehringer Ingelheim Investigational Site
      • Nanjing, Kina
        • 1245.20.86043 Boehringer Ingelheim Investigational Site
      • QingDao, Kina
        • 1245.20.86016 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1245.20.86004 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1245.20.86005 Boehringer Ingelheim Investigational Site
      • Shanghai, Kina
        • 1245.20.86006 Boehringer Ingelheim Investigational Site
      • Shenyang, Kina
        • 1245.20.86057 Boehringer Ingelheim Investigational Site
      • Shiyan, Kina
        • 1245.20.86017 Boehringer Ingelheim Investigational Site
      • Suzhou, Kina
        • 1245.20.86013 Boehringer Ingelheim Investigational Site
      • Taiyuan, Kina
        • 1245.20.86015 Boehringer Ingelheim Investigational Site
      • Wuhan, Kina
        • 1245.20.86009 Boehringer Ingelheim Investigational Site
      • Xi'An, Kina
        • 1245.20.86011 Boehringer Ingelheim Investigational Site
      • Xiamen, Kina
        • 1245.20.86014 Boehringer Ingelheim Investigational Site
  • Schweiz
      • Lugano, Schweiz
        • 1245.20.41004 Boehringer Ingelheim Investigational Site
      • Rorschach, Schweiz
        • 1245.20.41003 Boehringer Ingelheim Investigational Site
  • Tyskland
      • Dresden, Tyskland
        • 1245.20.49013 Boehringer Ingelheim Investigational Site
      • Düsseldorf, Tyskland
        • 1245.20.49016 Boehringer Ingelheim Investigational Site
      • Frankfurt, Tyskland
        • 1245.20.49015 Boehringer Ingelheim Investigational Site
      • Haag, Tyskland
        • 1245.20.49019 Boehringer Ingelheim Investigational Site
      • Hohenmölsen, Tyskland
        • 1245.20.49020 Boehringer Ingelheim Investigational Site
      • Köthen, Tyskland
        • 1245.20.49014 Boehringer Ingelheim Investigational Site
      • Neuwied, Tyskland
        • 1245.20.49002 Boehringer Ingelheim Investigational Site
      • Nürnberg, Tyskland
        • 1245.20.49008 Boehringer Ingelheim Investigational Site
      • Schauenburg, Tyskland
        • 1245.20.49022 Boehringer Ingelheim Investigational Site
      • St. Ingbert/Oberwürzbach, Tyskland
        • 1245.20.49017 Boehringer Ingelheim Investigational Site
      • Unterschneidheim, Tyskland
        • 1245.20.49003 Boehringer Ingelheim Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion criteria:

  1. Diagnosis of type 2 diabetes mellitus prior to informed consent;
  2. Male and female patients on diet and exercise regimen who are drug-naïve;
  3. HbA1c >= 7.0% and <= 10.0% at Visit 1 (screening) for randomised treatment; HbA1c > 10.0% at visit 1 (screening) for the open-label BI 10773 arm;
  4. Age >= 20 (Japan); Age >= 18 (countries other than Japan);
  5. BMI <= 45 kg/m2 at Visit 1 (screening);
  6. Signed and dated written informed consent by date of Visit 1

Exclusion criteria:

  1. Uncontrolled hyperglycaemia;
  2. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent;
  3. Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN;
  4. Impaired renal function (eGFR<50 ml/min);
  5. Bariatric surgery within the past two years or other GI surgeries;
  6. Medical history of cancer;
  7. Contraindications to sitagliptin;
  8. Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell;
  9. Treatment with any anti-diabetes drug within 12 weeks prior to randomisation;
  10. Treatment with anti-obesity drugs or any other treatment leading to unstable body weight;
  11. Current treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM;
  12. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and not practicing an acceptable method of birth control;
  13. Alcohol or drug abuse;
  14. Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial;
  15. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: BI 10773 low dose
Patients receive BI 10773 low dose tablets once daily
Medicin: BI 10773
BI 10773 lavdosis tablet én gang dagligt
Medicin: Placebo identical to BI10773 high dose
placebo tablets once daily
Medicin: Placebo identical to Sitagliptin 100mg
placebo tablets once daily
Eksperimentel: BI 10773 high dose
Patients receive BI 10773 high dose tablets once daily
Medicin: Placebo identical to Sitagliptin 100mg
placebo tablets once daily
Medicin: Placebo identical to BI10773 low dose
placebo tablets once daily
Medicin: BI10773
BI 10773 high dose tablets once daily
Placebo komparator: Placebo
Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
Medicin: Placebo identical to BI10773 high dose
placebo tablets once daily
Medicin: Placebo identical to Sitagliptin 100mg
placebo tablets once daily
Medicin: Placebo identical to BI10773 low dose
placebo tablets once daily
Aktiv komparator: Sitagliptin 100 mg
Patients receive Sitagliptin 100 mg tablets once daily
Medicin: Placebo identical to BI10773 high dose
placebo tablets once daily
Medicin: Placebo identical to BI10773 low dose
placebo tablets once daily
Medicin: Sitagliptin
Sitagliptin tablets 100 mg once daily
Eksperimentel: BI 10773 high dose open label
Patients receive BI 10773 high dose tablets open label once daily
Medicin: BI 10773 open label
Patients receive BI 10773 high dose tablets open label once daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks
Tidsramme: Baseline and day 169

The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).

In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.
Baseline and day 169

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline to Week 24 in Body Weight
Tidsramme: Baseline and day 169

The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).

In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.
Baseline and day 169
Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP)
Tidsramme: Baseline and week 24

The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm).

In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive.

For blood pressure, data following changes in antihypertensive therapy is censored, in the same way that data following initiation of rescue medication is censored.
Baseline and week 24

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Confirmed Hypoglycaemic Adverse Events
Tidsramme: From first drug intake until 7 days after last medication intake, up to 219 days

Confirmed hypoglycaemic events refer to all hypoglycaemic events, that had a glucose value <= 70 ml/dL or where assistance was required.

Symptomatic hypoglycaemic events were to be reported as adverse events. Patients can be counted in more than one category.
From first drug intake until 7 days after last medication intake, up to 219 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Boehringer Ingelheim

Samarbejdspartnere

Eli Lilly and Company

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 2010

Primær færdiggørelse (Faktiske)

1. marts 2012

Datoer for studieregistrering

Først indsendt

29. juli 2010

Først indsendt, der opfyldte QC-kriterier

6. august 2010

Først opslået (Skøn)

9. august 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

16. juni 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. maj 2014

Sidst verificeret

1. maj 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 1245.20
  • 2009-016243-20 (EudraCT nummer: EudraCT)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Diabetes mellitus, type 2

Kliniske forsøg med BI 10773

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Mexico

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner